AI Engines For more Details: Perplexity Kagi Labs You
Depression: Paroxetine hydrochloride is primarily prescribed for the treatment of depression. It works by increasing the levels of serotonin, a neurotransmitter, in the brain, which helps improve mood and alleviate depressive symptoms.
Anxiety Disorders: Paroxetine hydrochloride is also used to treat various anxiety disorders, including generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder, and obsessive-compulsive disorder (OCD).
Premenstrual Dysphoric Disorder (PMDD): Paroxetine hydrochloride may be prescribed to manage symptoms of PMDD, a severe form of premenstrual syndrome (PMS), such as mood swings, irritability, and physical symptoms.
Post-Traumatic Stress Disorder (PTSD): Paroxetine hydrochloride is sometimes used off-label to treat symptoms of PTSD, such as intrusive thoughts, flashbacks, nightmares, and hypervigilance.
Other Conditions: Paroxetine hydrochloride may also be prescribed off-label for conditions such as eating disorders, certain types of chronic pain, and menopausal symptoms.
Side Effects: Common side effects of paroxetine hydrochloride may include nausea, drowsiness, dry mouth, constipation, sweating, sexual dysfunction, and weight changes. These side effects are usually mild and may diminish over time. However, some individuals may experience more severe side effects or allergic reactions, such as rash, swelling, or difficulty breathing, which require immediate medical attention.
Withdrawal Symptoms: Discontinuing paroxetine hydrochloride abruptly or too rapidly may lead to withdrawal symptoms, commonly referred to as "discontinuation syndrome." These symptoms may include dizziness, headache, nausea, fatigue, irritability, and flu-like symptoms. It's essential to taper off the medication gradually under the supervision of a healthcare professional to minimize withdrawal effects.
Suicidal Thoughts and Behavior: Like other antidepressants, paroxetine hydrochloride may increase the risk of suicidal thoughts or behaviors, especially in children, adolescents, and young adults. Close monitoring is necessary, particularly when starting the medication or adjusting the dosage.
Serotonin Syndrome: In rare cases, the use of paroxetine hydrochloride may lead to serotonin syndrome, a potentially life-threatening condition characterized by dangerously high levels of serotonin in the brain. Symptoms may include agitation, hallucinations, rapid heartbeat, fever, excessive sweating, shivering, muscle stiffness, tremors, and loss of coordination. Seek immediate medical attention if you experience any of these symptoms.
Drug Interactions: Paroxetine hydrochloride can interact with other medications, including other antidepressants, certain pain medications, migraine drugs, blood thinners, and herbal supplements like St. John's wort. It's crucial to inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.
Pregnancy and Breastfeeding: The use of paroxetine hydrochloride during pregnancy may be associated with an increased risk of certain birth defects and complications, particularly if used during the first trimester. It may also pass into breast milk and potentially affect the nursing infant. If you are pregnant or breastfeeding, discuss the risks and benefits of using paroxetine hydrochloride with your healthcare provider.
Liver and Kidney Function: Paroxetine hydrochloride should be used with caution in individuals with impaired liver or kidney function, as the dosage may need to be adjusted based on the severity of impairment.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Cryptococcaceae | family | Decreases |
0 | 1 | Akkermansiaceae | family | Decreases |
1 | 0 | Cryptococcus | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Staphylococcus | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Leyella | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | unclassified Cryptococcus (in: basidiomycete fungi) | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Staphylococcus aureus | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Segatella bryantii | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Leyella stercorea | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Parolsenella catena | species | Decreases |
0 | 1 | Prevotella intermedia | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
0 | 1 | Leyella lascolaii | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
0 | 1 | Paraprevotella clara | species | Decreases |
0 | 1 | Prevotella bivia | species | Decreases |
0 | 1 | Prevotella dentalis | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
0 | 1 | Cryptococcus neoformans species complex | species group | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.5 | 0 | 0 |
ADHD | 1.1 | 0.1 | 10 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
Allergic Rhinitis (Hay Fever) | 1.4 | 0.7 | 1 |
Allergies | 2.8 | 1.6 | 0.75 |
Allergy to milk products | 1.3 | 0.3 | 3.33 |
Alopecia (Hair Loss) | 0.2 | 0.2 | |
Alzheimer's disease | 1.4 | 2 | -0.43 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.8 | 1.25 |
Ankylosing spondylitis | 2.6 | 0.4 | 5.5 |
Anorexia Nervosa | 0.1 | 0.8 | -7 |
Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
Asthma | 1.8 | 1.1 | 0.64 |
Atherosclerosis | 0.9 | 0.3 | 2 |
Atrial fibrillation | 1.3 | 1.7 | -0.31 |
Autism | 2.9 | 3.3 | -0.14 |
Autoimmune Disease | 0.4 | 0.1 | 3 |
benign prostatic hyperplasia | 0.7 | 0 | 0 |
Biofilm | 1.6 | 1.6 | |
Bipolar Disorder | 0.5 | 0.2 | 1.5 |
Brain Trauma | 0.7 | 0.4 | 0.75 |
Breast Cancer | 0.5 | 0.5 | |
Cancer (General) | 0.9 | -0.9 | |
Carcinoma | 0.6 | 0.3 | 1 |
Celiac Disease | 1 | 0.4 | 1.5 |
Cerebral Palsy | 0.2 | 0.1 | 1 |
Chronic Fatigue Syndrome | 1.4 | 1 | 0.4 |
Chronic Kidney Disease | 1.3 | 1.2 | 0.08 |
Chronic Lyme | 0.3 | 0.1 | 2 |
Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.2 | 4.5 |
Chronic Urticaria (Hives) | 0.8 | 1 | -0.25 |
Coagulation / Micro clot triggering bacteria | 1.4 | 0.1 | 13 |
Cognitive Function | 0.2 | 0.1 | 1 |
Colorectal Cancer | 1.9 | 1.3 | 0.46 |
Constipation | 0.6 | 0.1 | 5 |
Coronary artery disease | 2.1 | 0.9 | 1.33 |
COVID-19 | 2.9 | 3.4 | -0.17 |
Crohn's Disease | 2.5 | 1.9 | 0.32 |
Cushing's Syndrome (hypercortisolism) | 0.5 | 0 | 0 |
cystic fibrosis | 1.3 | 0.2 | 5.5 |
d-lactic acidosis (one form of brain fog) | 1 | 1 | |
deep vein thrombosis | 1.7 | 0.1 | 16 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 2.5 | 3.8 | -0.52 |
Dermatomyositis | 0.5 | 0 | 0 |
Eczema | 1.5 | 0.1 | 14 |
Endometriosis | 1.7 | 0.7 | 1.43 |
Epilepsy | 1.4 | 0.6 | 1.33 |
erectile dysfunction | 0.4 | 0 | 0 |
Fibromyalgia | 0.7 | 0.8 | -0.14 |
Functional constipation / chronic idiopathic constipation | 1.9 | 1.1 | 0.73 |
gallstone disease (gsd) | 1.2 | 0.2 | 5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.2 | -1 |
Generalized anxiety disorder | 1.6 | 0.3 | 4.33 |
Gout | 0.7 | 0.4 | 0.75 |
Graves' disease | 0.2 | 0.3 | -0.5 |
Gulf War Syndrome | 0.1 | 0.6 | -5 |
Halitosis | 0 | 0 | |
Hashimoto's thyroiditis | 0.4 | 0.3 | 0.33 |
Heart Failure | 2.4 | 0.9 | 1.67 |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
High Histamine/low DAO | 0.8 | 0 | 0 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.3 | 0.67 |
hyperglycemia | 1.2 | 0.6 | 1 |
Hyperlipidemia (High Blood Fats) | 0.4 | 0.2 | 1 |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 1.5 | 1 | 0.5 |
Hypothyroidism | 1.3 | 0.2 | 5.5 |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 0.6 | 1.3 | -1.17 |
Inflammatory Bowel Disease | 2.8 | 3.7 | -0.32 |
Insomnia | 0.9 | 1.2 | -0.33 |
Intelligence | 0.6 | 0.6 | 0 |
Intracranial aneurysms | 0.2 | 0.2 | 0 |
Irritable Bowel Syndrome | 2.5 | 1.1 | 1.27 |
ischemic stroke | 0.7 | 1 | -0.43 |
Liver Cirrhosis | 2.5 | 1.5 | 0.67 |
Long COVID | 1.8 | 1.9 | -0.06 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.4 | 0.4 | 0 |
Lymphoma | 0.4 | 0.4 | |
Mast Cell Issues / mastitis | 1.2 | 0.1 | 11 |
ME/CFS with IBS | 0.3 | -0.3 | |
ME/CFS without IBS | 0.4 | 0.1 | 3 |
Menopause | 0 | 0.2 | 0 |
Metabolic Syndrome | 2.5 | 1.1 | 1.27 |
Mood Disorders | 2.3 | 3.7 | -0.61 |
multiple chemical sensitivity [MCS] | 0.2 | 0.1 | 1 |
Multiple Sclerosis | 2.5 | 1.7 | 0.47 |
Multiple system atrophy (MSA) | 0.5 | 0.1 | 4 |
myasthenia gravis | 0.4 | 0.1 | 3 |
neuropathic pain | 0 | 0.4 | 0 |
Neuropathy (all types) | 0.3 | 0.3 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2 | 1.6 | 0.25 |
NonCeliac Gluten Sensitivity | 0.6 | 0.1 | 5 |
Obesity | 3.5 | 2.5 | 0.4 |
obsessive-compulsive disorder | 1.6 | 1.9 | -0.19 |
Osteoarthritis | 1.2 | 0.2 | 5 |
Osteoporosis | 1 | 0.4 | 1.5 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 3.1 | 2.6 | 0.19 |
Polycystic ovary syndrome | 1.1 | 0.3 | 2.67 |
Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
Premenstrual dysphoric disorder | 0.3 | 0.3 | |
primary biliary cholangitis | 0.2 | -0.2 | |
Primary sclerosing cholangitis | 0 | 0.6 | 0 |
Psoriasis | 1.9 | 1.7 | 0.12 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.2 | 1.1 | 1.91 |
Rosacea | 0.3 | 0.1 | 2 |
Schizophrenia | 1.1 | 0.5 | 1.2 |
scoliosis | 1.1 | 0.2 | 4.5 |
sensorineural hearing loss | 0.5 | 0.5 | |
Sjögren syndrome | 1.1 | 0.6 | 0.83 |
Sleep Apnea | 0.3 | 0.2 | 0.5 |
Slow gastric motility / Gastroparesis | 0.5 | 0 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0 | 0 |
Stress / posttraumatic stress disorder | 1.2 | 0.7 | 0.71 |
Systemic Lupus Erythematosus | 2 | 0.3 | 5.67 |
Tic Disorder | 1 | -1 | |
Tourette syndrome | 0.2 | 0 | 0 |
Type 1 Diabetes | 1.4 | 0.5 | 1.8 |
Type 2 Diabetes | 3 | 1.9 | 0.58 |
Ulcerative colitis | 1.9 | 1.6 | 0.19 |
Unhealthy Ageing | 0.8 | 0.9 | -0.13 |
Vitiligo | 0.2 | 0.3 | -0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]